Compare AU

Compare CURE vs. GRNV

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the VanEck MSCI Australian Sustainable Equity ETF (GRNV). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

GRNV

Popularity

Low

Low

Pearlers invested

83

580

Median incremental investment

$619.50

$670.48

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$1,388.94

Average age group

> 35

26 - 35


Key Summary

CURE

GRNV

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

GRNV.AX was created on 2016-04-27 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. GRNV.AX gives investors access to a diversified portfolio of sustainable Australian companies selected on the basis of in-depth analysis by world leading research agency MSCI ESG Research. GRNV.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index.

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

Westpac Banking Corp (5.04 %)

Goodman Group (5.01 %)

Telstra Group Ltd (4.99 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Financials (29.07 %)

Industrials (20.16 %)

Real Estate (12.06 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Australia (94.04 %)

New Zealand (3.05 %)

United States (2.91 %)

Management fee

0.45 %

0.35 %


Key Summary

CURE

GRNV

Issuer

Global X

VanEck

Tracking index

S&P Biotechnology Select Industry

MSCI Australia IMI Select SRI Screened Index - AUD

Asset class

ETF

ETF

Management fee

0.45 %

0.35 %

Price

$52.68

$33.10

Size

$36.301 million

$188.473 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

4.15 %

Market

ASX

ASX

First listed date

12/11/2018

02/05/2016

Purchase fee

$6.50

$6.50


Community Stats

CURE

GRNV

Popularity

Low

Low

Pearlers invested

83

580

Median incremental investment

$619.50

$670.48

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$1,388.94

Average age group

> 35

26 - 35


Pros and Cons

CURE

GRNV

Pros

  • Higher exposure to US market

  • Higher distribution yield

  • Higher exposure to AU market

  • Lower management fee

  • Higher price growth

Cons

  • Lower exposure to AU market

  • Higher management fee

  • Lower price growth

  • Lower exposure to US market

  • Lower distribution yield

CURE

GRNV

Lower exposure to AU market

Higher exposure to AU market

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home